4DMT Presents Positive Interim Data from Randomized Phase 2

51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden...

Related Keywords

Nevada ,United States ,Japan ,Reno ,David Kirn ,Katherine Smith ,Robert Kim ,Julian Pei ,Arshadm Khanani ,Clinic Research At Sierra Eye Associates ,Program Updates ,European Union ,Corporate Communications ,Clinical Data Program ,Linkedin ,Exchange Commission ,Nasdaq ,Molecular Therapeutics ,Chief Executive Officer ,Chief Medical ,Clinic Research ,Sierra Eye Associates ,Trial Dose Expansion Cohort Background ,Summary Baseline ,Dose Expansion ,Interim Results ,Treatment Diabetic Retinopathy Study ,Term Follow Up Update ,Population Extension ,Expansion Phase ,Webcast Details ,Treatment Burden ,Interim Clinical Data ,Therapeutic Vector Evolution ,Nobel Prize Winning ,Looking Statements ,Private Securities Litigation Reform Act ,Molecular Therapeutic ,Quarterly Report ,Investor Relations ,Nasdaq Fdmt ,4d Molecular Therapeutics ,Nc ,